STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACAD
  4. [Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity

ACADIA (NASDAQ: ACAD) director Adora Ndu exercises RSUs and receives new option, RSU grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS INC director Adora Ndu reported equity compensation activity and an option exercise. On May 29, 2026, Ndu exercised restricted stock units covering 8,107 shares of common stock, bringing direct common stock holdings to 32,908 shares.

Ndu also received 9,311 new restricted stock units and 16,004 director stock options with an exercise price of $21.66 per share. According to the footnotes, the 9,311 restricted stock units will vest in full on the earlier of one year after grant or the next annual stockholder meeting, while the options vest quarterly over one year on a similar schedule. The filing shows compensation-related awards and conversions, with no open-market purchases or sales.

Positive

  • None.

Negative

  • None.

Insights

Routine director equity awards and RSU exercise, no open-market trades.

Director Adora Ndu exercised restricted stock units into 8,107 shares of ACADIA PHARMACEUTICALS common stock and reported 32,908 shares held directly afterward. This converts prior equity-based compensation into outright share ownership.

The filing also shows new grants of 9,311 restricted stock units and 16,004 director stock options with a $21.66 exercise price. Footnotes describe standard vesting over one year or until the next annual meeting, indicating ongoing, performance-neutral board compensation rather than discretionary trading.

No open-market buys or sells are reported, and derivativeSummary is empty after the RSU exercise, suggesting the prior RSU award was fully converted. Overall, this is a routine equity compensation update without a clear bullish or bearish signal.

Insider Ndu Adora
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 8,107 $0.00 --
Grant/Award Director Stock Options (Right to Buy) 16,004 $0.00 --
Grant/Award Restricted Stock Units 9,311 $0.00 --
Exercise Common Stock 8,107 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Director Stock Options (Right to Buy) — 16,004 shares (Direct, null); Common Stock — 32,908 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.
RSU shares exercised 8,107 shares Restricted stock units converted to common stock on May 29, 2026
Common shares held after exercise 32,908 shares Direct ownership following RSU exercise
New RSU grant 9,311 units Restricted stock units granted on May 29, 2026
New director stock options 16,004 options Director stock options granted on May 29, 2026
Option exercise price $21.66 per share Exercise price of director stock options expiring May 28, 2036
Derivative exercises reported 1 transaction, 8,107 shares Exercise of derivative security per transactionSummary
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Director Stock Options (Right to Buy) financial
"Director Stock Options (Right to Buy) with an exercise price of 21.6600 per share."
vested in full financial
"The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held."
annual meeting of stockholders regulatory
"The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders."
exercise price financial
"The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ndu Adora
(Last)(First)(Middle)
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/29/2026M8,107A(1)32,908D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)05/29/2026M8,107 (2) (2)Common Stock8,107$00D
Director Stock Options (Right to Buy)$21.6605/29/2026A16,004 (3)05/28/2036Common Stock16,004$016,004D
Restricted Stock Units(1)05/29/2026A9,311 (4) (4)Common Stock9,311$09,311D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
2. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
3. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
4. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.
/s/ Jennifer J. Rhodes, Attorney-in-Fact06/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Adora Ndu report for ACAD (ACADIA PHARMACEUTICALS)?

Adora Ndu reported exercising restricted stock units into 8,107 shares of common stock and receiving 9,311 new restricted stock units plus 16,004 director stock options. All transactions occurred on May 29, 2026 and are compensation-related, not open-market trades.

How many ACAD common shares does Adora Ndu hold after this Form 4?

After the reported transactions, Adora Ndu holds 32,908 shares of ACAD common stock directly. This reflects the conversion of 8,107 restricted stock units into shares, as disclosed in the Form 4, and gives context for the scale of the director’s equity position.

What equity awards did ACADIA PHARMACEUTICALS grant to director Adora Ndu?

ACADIA PHARMACEUTICALS granted Adora Ndu 9,311 restricted stock units and 16,004 director stock options with a $21.66 exercise price. Footnotes state the options vest quarterly over one year, while the restricted stock units vest in full after roughly one year or at the next annual meeting.

Were there any open-market stock purchases or sales in this ACAD Form 4?

No open-market purchases or sales were reported. The filing shows an exercise of 8,107 restricted stock units into common stock and new grants of restricted stock units and stock options, all categorized as compensation-related acquisitions rather than discretionary market trades.

How do the new ACADIA director stock options for Adora Ndu vest?

The 16,004 director stock options vest quarterly over one year following the grant date. According to the footnotes, the final tranche vests on the earlier of one year after the grant or the next annual meeting of stockholders, reflecting a typical short board vesting schedule.

When do Adora Ndu’s new ACAD restricted stock units vest?

The 9,311 restricted stock units granted to Adora Ndu will vest in full on the earlier of one year following the grant date or the next annual meeting of stockholders. Each restricted stock unit represents a contingent right to receive one share of ACAD common stock upon vesting.